SGX942 Receives Fast Track Designation for Oral Mucositis

June 2013, Vol 4, No 5

The FDA has granted a fast track designation for the development of SGX942 (Soligenix) for the treatment of oral mucositis associated with radiation and/or chemotherapy used in patients with head and neck cancer. SGX942 is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability. Extensive in vivo preclinical studies have demonstrated a significant reduction in tissue damage associated with chemotherapy, radiation, trauma, and inflammation. (June 2, 2013)

Related Articles